Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
Data updated
Research Footprint
Yvan Beaussant appears in 7 tracked papers (2021–2025), most studied alongside Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Anxiety Disorders.
Most-cited paper: Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder (69 citations).
Frequent co-authors: Manish Agrawal, Stephen Ross and Brian Anderson.
Background & Research
Yvan Beaussant, MD, MSc, is a French-trained hematologist and palliative care physician based at Dana-Farber Cancer Institute and Harvard Medical School. His research focuses on psychedelic-assisted therapies in serious illness, including psilocybin studies for cancer patients, hospice patients, and older adults, as well as broader work defining priorities for psychedelic research in palliative care.
Key Impact
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Yvan Beaussant is associated with.
Dana-Farber Cancer Institute
A U.S. cancer center and academic clinical institution in Boston delivering oncology care and conducting translational and clinical research.
View stakeholder →Brigham and Women's Hospital
Major academic medical center in Boston affiliated with Harvard Medical School and part of the Mass General Brigham health system. Researchers at BWH are active in the emerging field of psychedelic-assisted therapy, including psilocybin studies for gastrointestinal conditions and ethical frameworks for psychedelic pain research.
View stakeholder →